{Reference Type}: Journal Article
{Title}: Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study.
{Author}: Tian J;Wang H;Lu C;Liu L;Zhang X;Xie Y;Li R;Lv X;Fu D;Zhang L;Fang X;Wang X;Hu J;Liu X;Huang X;Zhao Q;Luo N;Tang H;Zhong Z;He Y;Li L;
{Journal}: Lung Cancer
{Volume}: 181
{Issue}: 0
{Year}: 2023 07 20
{Factor}: 6.081
{DOI}: 10.1016/j.lungcan.2023.107255
{Abstract}: Microsatellite instability (MSI) is the first pan-cancer biomarker approved to guide immune checkpoint inhibitor therapy for MSI-high (MSI-H) solid tumors. In lung cancer, the MSI-H frequency is very low, and the genetic characteristics and prognosis of lung cancer with MSI-H were rarely reported.<BR>Next-generation sequencing and immunohistochemistry were used detect MSI status, tumor mutation burden (TMB) and PD-L1 expression.<BR>Among 12,484 lung cancer patients screened, 66 were found with MSI-H, the proportion was as low as 0.5%. Compared with Microsatellite stability (MSS), TMB was higher in MSI-H lung cancer patients, while PD-L1 expression showed no considerable difference between MSI-H and MSS. After propensity score matching, compared with MSS, the most common companion mutations in MSI-H were TP53, BRCA2, TGFBR2, PTEN and KMT2C. In MSI-H lung adenocarcinoma with EGFR mutation, TGFBR2 and ERBB2 had higher mutation frequency than in MSS.<BR>The current study reveals the genetic characteristics of MSI-H lung cancer, which advanced our understanding of MSI-H lung cancer.